Get started

Longidea

LNTH right direction as business and the price could improveLNTH recently purchased cancer drugs license which are in the Phase 1 with FDA, that look promising. The company raised some cash through senior convertible notes. Quarterly revenue grew 134% YoY to $239.3mm, driven by strengths across the portfolio. Management raised Q4 and FY22 guidance to the upside from the top-bottom lines. Last ER looks like: Lantheus Non-GAAP EPS of $0.99 beats by $0.16, revenue of $239.29M beats by $11.41M. The stock price retraced to its long term support zone and could start move up towards 80$ area.
NASDAQ:LNTHLong
by alpha62539
2
ADA Accumulation zone of 5 month descending wedgeHi Tradingview, BINANCE:ADAUSDT ADA Has been trading in a descending wedge on the DAILY time frame for the last 5 months. It is currently at the bottom of the wedge and has held support quite well. We can also see the the TSI has recently crossed, however it is still under (0) so bears are still in control. I am looking to enter a position with the parameters as follows: Entry: .309 SL: Below .29 TP1: .328 TP2: .33 TP3: .368 TP4: .40 TP5: .46
Long
by Spikecaptial